SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Claud B who wrote (4013)5/9/1998 12:28:00 AM
From: Bradpalm1  Respond to of 7041
 
<<...why did no one find fault with his work on Viagra?>>

Dr. Goldstein and other ED experts hardly had to go out on a limb in order to enthusiastically support Viagra. Why isn't there similar support for Vasomax? I think we both know why.

Bradpalm1



To: Claud B who wrote (4013)5/9/1998 1:11:00 AM
From: Tokyo VD  Read Replies (2) | Respond to of 7041
 
Claud,

Once again, you are wrong. Pfizer did find fault with Dr. Goldstein, that is why they no longer employ him as a consultant or retain him as a clinical investigator. In fact, Pfizer wouldn't even sit on the panel meeting with Goldstein (Vivus, Zonagen, and TAP Pharma did) at the Cowen Healthcare conference (even though Pfizer did present their data later that day).

Tokyo


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News